• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

AbbVie's post-Humira stalwarts Skyrizi, Rinvoq performing exactly as hoped, CEO says

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 31, 2021 at 10:12: PM
via AbbVie is relying on its next-gen immunology drugs Skyrizi and Rinvoq to fill what will be a massive sales gap once blockbuster Humira faces generic foes in the U.S. And as the company sees it, everything is going according to plan.

article source
 




Top Bottom
Back
Quote